109 related articles for article (PubMed ID: 38736192)
1. Exogenous steroid replacement in a pediatric patient with adrenocortical carcinoma receiving mitotane.
Martin CE; Kuhn AK; Leopold KN; Creo AL; Schoettler PJ; Allen-Rhoades WA
Pediatr Blood Cancer; 2024 May; ():e31072. PubMed ID: 38736192
[No Abstract] [Full Text] [Related]
2. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations.
Abrahamsson G; Ekerhovd E; Janson PO; Jansson S; Ahlman H; Wängberg B; Norström A
Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1297-1302. PubMed ID: 32282928
[TBL] [Abstract][Full Text] [Related]
4. Clinical results of the use of mitotane for adrenocortical carcinoma.
Kasperlik-Zaluska AA
Braz J Med Biol Res; 2000 Oct; 33(10):1191-6. PubMed ID: 11004719
[TBL] [Abstract][Full Text] [Related]
5. Practical treatment using mitotane for adrenocortical carcinoma.
Terzolo M; Zaggia B; Allasino B; De Francia S
Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405
[TBL] [Abstract][Full Text] [Related]
6. Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor.
Oddie PD; Albert BB; Hofman PL; Jefferies C; Laughton S; Carter PJ
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 30159150
[TBL] [Abstract][Full Text] [Related]
7. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
Lecka A; Ginalska-Malinowska M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
[TBL] [Abstract][Full Text] [Related]
9. Effects of mitotane treatment on human steroid metabolism: implications for patient management.
Ghataore L; Chakraborti I; Aylwin SJ; Schulte KM; Dworakowska D; Coskeran P; Taylor NF
Endocr Connect; 2012 Jul; 1(1):37-47. PubMed ID: 23781302
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive treatment of adrenocortical carcinoma.
Terzolo M; Berruti A
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
[TBL] [Abstract][Full Text] [Related]
11. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB
Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
Kroiss M; Quinkler M; Lutz WK; Allolio B; Fassnacht M
Clin Endocrinol (Oxf); 2011 Nov; 75(5):585-91. PubMed ID: 21883349
[TBL] [Abstract][Full Text] [Related]
13. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.
Riedmeier M; Antonini SRR; Brandalise S; Costa TEJB; Daiggi CM; de Figueiredo BC; de Krijger RR; De Sá Rodrigues KE; Deal C; Del Rivero J; Engstler G; Fassnacht M; Fernandes Luiz Canali GC; Molina CAF; Gonc EN; Gültekin M; Haak HR; Guran T; Hendriks Allaird EJ; Idkowiak J; Kuhlen M; Malkin D; Meena JP; Pamporaki C; Pinto E; Puglisi S; Ribeiro RC; Thompson LDR; Yalcin B; Van Noesel M; Wiegering V
Eur J Endocrinol; 2024 Mar; 190(4):G15-G24. PubMed ID: 38552173
[TBL] [Abstract][Full Text] [Related]
14. Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.
Salenave S; Bernard V; Do Cao C; Guignat L; Bachelot A; Leboulleux S; Droumaguet C; Bry-Gauillard H; Pierre P; Crinière L; Santulli P; Touraine P; Chanson P; Schlumberger M; Maiter D; Baudin E; Young J
Eur J Endocrinol; 2015 Feb; 172(2):141-9. PubMed ID: 25411236
[TBL] [Abstract][Full Text] [Related]
15. Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma.
Tada H; Nohara A; Kawashiri MA; Inazu A; Mabuchi H; Yamagishi M
J Atheroscler Thromb; 2014; 21(12):1326-9. PubMed ID: 25392159
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane.
Kobayakawa Y; Hamamoto S; Kamisawa H; Okada S; Taguchi K; Naiki T; Okada A; Tozawa K; Yasui T
IJU Case Rep; 2022 Jul; 5(4):288-292. PubMed ID: 35795129
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M; Fassnacht M; Perotti P; Libé R; Kastelan D; Lacroix A; Arlt W; Haak HR; Loli P; Decoudier B; Lasolle H; Quinkler M; Haissaguerre M; Chabre O; Caron P; Stigliano A; Giordano R; Zatelli MC; Bancos I; Fragoso MCBV; Canu L; Luconi M; Puglisi S; Basile V; Reimondo G; Kroiss M; Megerle F; Hahner S; Kimpel O; Dusek T; Nölting S; Bourdeau I; Chortis V; Ettaieb MH; Cosentini D; Grisanti S; Baudin E; Berchialla P; Bovis F; Sormani MP; Bruzzi P; Beuschlein F; Bertherat J; Berruti A
Lancet Diabetes Endocrinol; 2023 Oct; 11(10):720-730. PubMed ID: 37619579
[TBL] [Abstract][Full Text] [Related]
18. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
[TBL] [Abstract][Full Text] [Related]
19. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
[TBL] [Abstract][Full Text] [Related]
20. Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer.
Basile V; Puglisi S; Calabrese A; Pia A; Perotti P; Berruti A; Reimondo G; Terzolo M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32937772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
